Opinion
Video
The impact of compounding liver-directed and systemic therapies in HCC management is discussed by Drs Morse and Covey.
FDA Accepts BLA Resubmission for Zolbetuximab in CLDN18.2+ Advanced Gastric/GEJ Adenocarcinoma
Oncology Experts Preview Top Abstracts From the 2024 ASCO Annual Meeting
Revisit Every OncLive On Air Episode From May 2024
D'Amato Discusses Research and Resistance Mechanisms in Sarcoma and Gastrointestinal Stromal Tumor
FDA Grants Priority Review to Zanidatamab for HER2+ Metastatic Biliary Tract Cancer
CT041 Shows Tolerability and Early Efficacy in Refractory Metastatic Pancreatic Cancer
Asciminib Bests Standard-of-Care TKIs in Ph+ CML
Lorlatinib Yields Longest Reported PFS in Advanced NSCLC
Rivoceranib Plus Camrelizumab Maintains Frontline Survival Benefit in Unresectable HCC
Dr Pal Previews ASCO 2024 Data in Renal Cell Carcinoma